Hyperlipoproteinemia: Difference between revisions
Jump to navigation
Jump to search
Tarek Nafee (talk | contribs) No edit summary |
Tarek Nafee (talk | contribs) No edit summary |
||
Line 4: | Line 4: | ||
== Overview == | == Overview == | ||
== Classification == | |||
{{familytree/start |summary=Hyperlipoproteinemia}} | |||
{{familytree | | | | | | | | | | | | | | A01 | | | | | | | | | | | | | A01= '''Hyperlipoproteinemia'''}} | |||
{{familytree | | | | | |,|-|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|.| | | | }} | |||
{{familytree | | | | | D01 | | | D02 | | D03 | | D04 | | D05 | | D01= '''Type I:'''<br> [[Familial hyperchylomicronemia]]| D02= '''Type II'''| D03= '''Type III:'''<br>[[Dysbetalipoproteinemia]]| D04= '''Type IV:'''<br>[[Primary hypertriglyceridemia]]<br>| D05= '''Type V:''' <br>[[Mixed hyperlipoproteinemia]]}} | |||
{{familytree | | | | | | | | |,|-|^|-|.| | |}} | |||
{{familytree | | | | | | | | E01 | | E02 | | E01= '''Type A:'''<br> [[Familial hypercholesterolemia]]| E02= '''Type B:'''<br> [[Familial combined hyperlipidemia]]}} | |||
{{familytree/end}} | |||
== Synopsis == | == Synopsis == | ||
{| class="sortable" border="1" cellpadding="5" cellspacing="0" align="center" | {| class="sortable" border="1" cellpadding="5" cellspacing="0" align="center" | ||
Line 321: | Line 329: | ||
|} | |} | ||
==References== | ==References== |
Revision as of 21:40, 8 November 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Classification
Hyperlipoproteinemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Type I: Familial hyperchylomicronemia | Type II | Type III: Dysbetalipoproteinemia | Type IV: Primary hypertriglyceridemia | Type V: Mixed hyperlipoproteinemia | |||||||||||||||||||||||||||||||||||||||||||||||||||
Type A: Familial hypercholesterolemia | Type B: Familial combined hyperlipidemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Synopsis
Hyperlipoproteinemia | Synonyms | Problems | Labs description | Treatment |
---|---|---|---|---|
Type I | Buerger-Gruetz syndrome, primary hyperlipoproteinaemia, or familial hyperchylomicronemia | Decreased lipoprotein lipase (LPL) or altered ApoC2 | Elevated chylomicrons | Diet control |
Type IIa | Polygenic hypercholesterolaemia or familial hypercholesterolemia | LDL receptor deficiency | Elevated LDL only | Bile acid sequestrants, statins, niacin |
Type IIb | Combined hyperlipidemia | Decreased LDL receptor and increased ApoB | Elevated LDL, VLDL and triglycerides | Statins, niacin, gemfibrozil |
Type III | Familial Dysbetalipoproteinemia | Defect in ApoE synthesis | Increased IDL | Drug of choice: Gemfibrozil |
Type IV | Endogenous Hyperlipemia | Increased VLDL production and decreased elimination | Increased VLDL | Drug of choice: Niacin |
Type V | Familial Hypertriglyceridemia | Increased VLDL production and decreased LPL | Increased VLDL and chylomicrons | Niacin, gemfibrozil |
Differential Diagnosis
Diseases | Mode of Inheritance | Laboratory Findings | Other Findings | Management | Complications | Prognosis | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lipid Profile | Other Laboratory Findings | |||||||||||||
Total Cholesterol | LDL | HDL | Triglycerides | Plasma Appearance | Chylomicrons | VLDL | Genetic mutations | |||||||
Primary Hyperlipoprotenemia | Type I | Autosomal Recessive | Normal or ↑ | Normal | Normal | ↑↑↑↑ | Creamy | LPL gene mutation | Chylomicrons
Elevated |
-Recurrent Pancreatitis
-Rarely life threatening |
Good | |||
Type IIA | ||||||||||||||
Type IIB | ||||||||||||||
Type III | ||||||||||||||
Type IV | ||||||||||||||
Type V | ||||||||||||||
Secondary Hyperlipoprotenemia | Diabetes Mellitus | |||||||||||||
Alcohol Abuse | ||||||||||||||
Estrogen Therapy | ||||||||||||||
Glucocorticoid therapy | ||||||||||||||
Renal Disease | ||||||||||||||
Obesity | ||||||||||||||
High-fat diet | ||||||||||||||
Poor physical activity | ||||||||||||||
Paraproteinemic disorders | ||||||||||||||
Hypothyroidism |